Immunotherapy

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.

What is Immunotherapy?

Immunotherapy is a treatment that is designed to harness the ability of the body’s immune system to combat infection or disease.

Suppression Immunotherapies

Immunotherapy and Helminthic Therapy

Immunotherapy: Past, Present and Future

Adoptive T Cell Therapy Applications

Immunotherapy: The Future of Lung Cancer Treatment?

Adoptive T Cell Therapy Methodology

Neoantigens' Role in Immunotherapy

Activation Immunotherapies

Latest Immunotherapy News and Research

Cornell study finds existing drug could boost liver cancer immunotherapy

Immunotherapy – which activates the body's own immune system to kill cancer cells – has not worked well against a rare and fatal liver cancer, but a new Cornell University study finds an existing FDA-approved drug may allow the immunotherapy to fight the cancer as intended, opening the door to a potential treatment.

17 Feb 2026

Preoperative combination treatment shows promise for some patients with pancreatic cancer

A new UCLA investigator-initiated study sponsored by the UCLA Health Jonsson Comprehensive Cancer Center has found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer, a disease that has historically been difficult to treat.

17 Feb 2026

Fred Hutch scientists reach crucial milestone in blocking Epstein Barr virus

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of cancer, neurodegenerative diseases and other chronic health conditions.

17 Feb 2026

Chronic inflammation shapes cancer progression and immunotherapy response

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

16 Feb 2026

Engineered Listeria boosts innate immunity against cancer

After nearly 40 years of research on how Listeria bacteria manipulate our cells and battle our immune system to cause listeriosis, Daniel Portnoy and his colleagues have discovered a way to turn the bacteria into a potent booster of the immune system - and a potential weapon against cancer.

13 Feb 2026

Novel antibody 007 targets the elusive HIV envelope epitope

HIV-1 can be neutralized by antibodies which bind to vulnerable structures on the virus surface. One such vulnerable site is the so-called V3 glycan site of the viral envelope protein.

13 Feb 2026

NHS updates bladder cancer chemotherapy guidelines

Hundreds of people with advanced bladder cancer across the UK can now receive three rather than six chemotherapy cycles following research by Queen Mary University of London which has led to a change to NHS treatment guidelines.

13 Feb 2026

ASH releases new guidelines for treating leukemia in adolescents and young adults

The American Society of Hematology (ASH) released guidelines on frontline management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), as well as the management of relapsed or refractory disease in this population.

12 Feb 2026

Rising lung cancer in never smokers demands urgent research focus

Lung cancer patients who have never smoked make up a significant and growing share of global lung cancer cases, yet remain an understudied group, according to a new review written by UCL (University College London) researchers.

12 Feb 2026

SLAMF6 discovery offers hope for non-responding cancer patients

Cancer researchers working on immunotherapies have made a big discovery: SLAMF6, a molecule on the surface of immune cells that prevents T cells from effectively attacking tumors – and, in mice, they've found a way to neutralize it.

12 Feb 2026

Alzheimer’s plaques decline after CAR-T immune cell treatment in preclinical study

Researchers engineered CD4+ chimeric antigen receptor T cells targeting fibrillar amyloid beta and tested them in a mouse Alzheimer model. The preclinical study showed reduced amyloid pathology and altered neuroimmune responses, supporting CAR-T immunotherapy as a potential future Alzheimer strategy.

11 Feb 2026